
NYSEHealthcareMedical - Instruments & Supplies
最新データ
$17.30
+$0.15 · +0.87%
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
前日終値
$17.30
+$0.15 · +0.87%
日中の時刻はETです。市場データは遅延する場合があります。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日中レンジ
現在 $17.30
52週レンジ
現在 $17.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
52
適正価値
センチメント
57
まちまち
リスク
31
中程度のリスク
モメンタム
41
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日中レンジ
現在 $17.30
52週レンジ
現在 $17.30
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 51.01億 USD | 47.91億 USD | 41.46億 USD | 37.68億 USD | 37.65億 USD |
| 売上原価 | 23.08億 USD | 18.72億 USD | 16.42億 USD | 15.19億 USD | 14.67億 USD |
| 粗利益 | 27.93億 USD | 29.19億 USD | 25.04億 USD | 22.49億 USD | 22.98億 USD |
| 研究開発 | 3.71億 USD | 3.43億 USD | 3.24億 USD | 3.07億 USD | 2.71億 USD |
| 販売・一般管理 | 22.34億 USD | 20.82億 USD | 17.36億 USD | 14.78億 USD | 13.89億 USD |
| 営業費用 | 26.05億 USD | 27.57億 USD | 23.74億 USD | 20.42億 USD | 19.69億 USD |
| 受取利息 | 1200万 USD | 1500万 USD | 1500万 USD | 600万 USD | — |
| 支払利息 | 4.31億 USD | 3.99億 USD | 2.83億 USD | 1.46億 USD | — |
| 減価償却費と償却費 | 4.21億 USD | 4.36億 USD | 3.82億 USD | 3.79億 USD | 4.15億 USD |
| 営業利益 | 1.88億 USD | 1.62億 USD | 1.3億 USD | 2.07億 USD | 3.29億 USD |
| 純利益 | −3.6億 USD | −3.17億 USD | −2.6億 USD | 600万 USD | 1.82億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.83
上昇余地(20.40%)この株式へのエクスポージャーを報告している上場投資信託です。
Ballast Small/Mid Cap ETFMGMT243.07万1.48%1.65億 USD1.17%$49.185-0.14%
Dimensional World ex U.S. Core Equity 2 ETFDFAX26.04万0.00%123.36億 USD0.28%$37.08+0.76%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN15.96万0.05%3.47億 USD0.47%$45.715+0.83%
Gotham 1000 Value ETFGVLU10.57万0.04%2.46億 USD0.65%$27.555-0.02%
Dimensional - International Core Equity 2 ETFDFIC4.39万0.00%150.17億 USD0.22%$37.53+0.64%
BNY Mellon US Small Cap Core Equity ETFBKSE2.88万0.03%8417.42万 USD0.04%$41.8954+0.42%
Ballast Small/Mid Cap ETFMGMT
Dimensional World ex U.S. Core Equity 2 ETFDFAX
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN
Gotham 1000 Value ETFGVLU
Dimensional - International Core Equity 2 ETFDFIC
BNY Mellon US Small Cap Core Equity ETFBKSEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。